Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis

References

• Ahn AC, Tewari M, Poon CS, Phillips RS. The limits of reductionism in medicine: Could systems biology offer an alternative?. PLoS Med 2006; 3(6)e208
   PubMed Web of Science ®Google Scholar
• Bar-Yam Y. Making things work: Solving complex problems in a complex world. Knowledge Press, Cambridge, CA 2005
   Google Scholar
• Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. Harrison's principles in internal medicine16th ed., E Braunwald, AD Fauci, DL Kasper, SL Hauser, DL Longo, JL Jameson. McGraw Hill, New York 2005; 2461–2471
   Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006; 129(Pt 3)606–616
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW, Hashimoto SA, Warren S, Hader W, Murray TJ, et al. A population-based study of multiple sclerosis in twins: Update. Ann Neurol 1993; 33(3)281–285
   PubMed Web of Science ®Google Scholar
• Mumford CJ, Wood NW, Kellar-Wood H, Thorpe JW, Miller DH, Compston DA. The British Isles survey of multiple sclerosis in twins. Neurology 1994; 44(1)11–15
   PubMed Web of Science ®Google Scholar
• Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006; 60(1)12–21
   PubMed Web of Science ®Google Scholar
• Hart BA, Amor S. The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system. Curr Opin Neurol 2003; 16(3)375–383
   PubMed Web of Science ®Google Scholar
• Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172(4)1193–1200
   PubMed Web of Science ®Google Scholar
• Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: Immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995; 45(6 Suppl 6)S44–S49
   Web of Science ®Google Scholar
• van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47(6)1531–1534
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36(12)1681–1690
   PubMed Web of Science ®Google Scholar
• Hale G, Swirsky DM, Hayhoe FG, Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1983; 1(3)321–334
   PubMedGoogle Scholar
• Heit W, Bunjes D, Wiesneth M, Schmeiser T, Arnold R, Hale G, Waldmann H, Heimpel H. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986; 64(3)479–486
   PubMed Web of Science ®Google Scholar
• Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 1993; 84(3)542–544
   PubMed Web of Science ®Google Scholar
• Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344(8918)298–301
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119(Pt 1)225–237
   PubMed Web of Science ®Google Scholar
• Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214(4524)1026–1028
   PubMed Web of Science ®Google Scholar
• Compston A, Sawcer S. Genetic analysis of multiple sclerosis. Curr Neurol Neurosci Rep 2002; 2(3)259–266
   PubMedGoogle Scholar
• Cooperative TTMSG. A meta-analysis of genomic screens in multiple sclerosis. Mult Scler 2001; 7(1)3–11
   PubMedGoogle Scholar
• Cooperative TTMSG, GAMES. A meta-analysis of whole genome linkage screens in multiple sclerosis. J Neuroimmunol 2003; 143(1–2)39–46
   PubMed Web of Science ®Google Scholar
• Barcellos LF, Oksenberg JR, Green AJ, Bucher P, Rimmler JB, Schmidt S, Garcia ME, Lincoln RR, Pericak-Vance MA, Haines JL, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002; 125(Pt 1)150–158
   PubMedGoogle Scholar
• Haines JL, Terwedow HA, Burgess K, Pericak-Vance MA, Rimmler JB, Martin ER, Oksenberg JR, Lincoln R, Zhang DY, Banatao DR, et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The multiple sclerosis genetics group. Hum Mol Genet 1998; 7(8)1229–1234
   PubMed Web of Science ®Google Scholar
• Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294(5547)1731–1735
   PubMed Web of Science ®Google Scholar
• Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8(5)500–508
   PubMed Web of Science ®Google Scholar
• Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13(4)554–573
   PubMed Web of Science ®Google Scholar
• Lindberg RL, De Groot CJ, Certa U, Ravid R, Hoffmann F, Kappos L, Leppert D. Multiple sclerosis as a generalized CNS disease-comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J Neuroimmunol 2004; 152(1–2)154–167
   PubMed Web of Science ®Google Scholar
• Baranzini SE, Oksenberg JR, Hauser SL. New insights into the genetics of multiple sclerosis. J Rehabil Res Dev 2002; 39(2)201–209
   PubMedGoogle Scholar
• Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity. Ann Neurol 2004; 55(3)410–417
   PubMed Web of Science ®Google Scholar
• Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: Specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004; 138(1)164–170
   PubMed Web of Science ®Google Scholar
• Satoh J, Nakanishi M, Koike F, Miyake S, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis 2005; 18(3)537–550
   PubMed Web of Science ®Google Scholar
• Satoh J, Nakanishi M, Koike F, Onoue H, Aranami T, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J Neuroimmunol 2006; 174(1–2)108–118
   PubMed Web of Science ®Google Scholar
• van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006
   PubMed Web of Science ®Google Scholar
• Matejuk A, Hopke C, Dwyer J, Subramanian S, Jones RE, Bourdette DN, Vandenbark AA, Offner H. CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis. J Neurosci Res 2003; 73(5)667–678
   PubMed Web of Science ®Google Scholar
• Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. cDNA microarray analysis in multiple sclerosis lesions: Detection of genes associated with disease activity. Brain 2003; 126(Pt 5)1048–1057
   PubMedGoogle Scholar
• Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin Neurol Neurosurg 2004; 106(3)223–229
   PubMed Web of Science ®Google Scholar
• Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM, Tourtellotte WW, Griffiths LR. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 2003; 119(2)170–183
   PubMedGoogle Scholar
• Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59(3)478–489
   PubMed Web of Science ®Google Scholar
• Liebman MN. Biomedical informatics: The future for drug development. Drug Discov Today 2002; 7(20 Suppl)S197–S203
   PubMed Web of Science ®Google Scholar
• Bolouri H, Davidson EH. Modeling transcriptional regulatory networks. Bioessays 2002; 24(12)1118–1129
   PubMed Web of Science ®Google Scholar
• Wolfson C, Confavreux C. A Markov model of the natural history of multiple sclerosis. Neuroepidemiology 1985; 4(4)227–239
   PubMedGoogle Scholar
• Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343(20)1430–1438
   PubMed Web of Science ®Google Scholar
• Volterra V. Variations and fluctuations of the number of individuals in animal species living together. Animal ecology. McGraw-Hill, New York 1931
   Google Scholar
• Chen KC, Calzone L, Csikasz-Nagy A, Cross FR, Novak B, Tyson JJ. Integrative analysis of cell cycle control in budding yeast. Mol Biol Cell 2004; 15(8)3841–3862
   PubMed Web of Science ®Google Scholar
• Wolfram S. A new kind of science. Wolfram Media Inc, Champaign, IL 2002
   Google Scholar
• Kauffman SA. The origins of order: Self-organization and selection in evolution. Oxford University Press, New York 1993; Vol. xviii: 709
   Google Scholar
• Huang WX, Huang P, Link H, Hillert J. Cytokine analysis in multiple sclerosis by competitive RT-PCR: A decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression [comment]. Mult Scler 1999; 5(5)342–348
   PubMedGoogle Scholar
• Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6)707–717
   PubMed Web of Science ®Google Scholar
• Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 2004; 63(12 Suppl 6)S41–S46
   Web of Science ®Google Scholar
• Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006; 116(4)1037–1044
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Bakshi R. Combination therapy for multiple sclerosis: The treatment strategy of the future?. CNS Drugs 2004; 18(12)777–792
   PubMed Web of Science ®Google Scholar
• Chang TT, Jabs C, Sobel RA, Kuchroo VK, Sharpe AH. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med 1999; 190(5)733–740
   PubMed Web of Science ®Google Scholar
• Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003; 4(9)899–906
   PubMed Web of Science ®Google Scholar
• Lev N, Barhum Y, Melamed E, Offen D. Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice. Neurosci Lett 2004; 359(3)139–142
   PubMed Web of Science ®Google Scholar
• Ye Q, Press B, Kissler S, Yang XF, Lu L, Bassing CH, Sleckman BP, Jansson M, Panoutsakopoulou V, Trimble LA, et al. T cell costimulation through CD28 depends on induction of the Bcl-xgamma isoform: Analysis of Bcl-xgamma-deficient mice. J Exp Med 2002; 196(1)87–95
   PubMed Web of Science ®Google Scholar
• Calida DM, Constantinescu C, Purev E, Zhang GX, Ventura ES, Lavi E, Rostami A. Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J Immunol 2001; 166(2)723–726
   PubMed Web of Science ®Google Scholar
• Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 1999; 163(5)2403–2409
   PubMed Web of Science ®Google Scholar
• Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192(6)899–905
   PubMed Web of Science ®Google Scholar
• Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30(5)1410–1415
   PubMed Web of Science ®Google Scholar
• Murphy CA, Hoek RM, Wiekowski MT, Lira SA, Sedgwick JD. Interactions between hemopoietically derived TNF and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J Immunol 2002; 169(12)7054–7062
   PubMed Web of Science ®Google Scholar
• Teige A, Teige I, Lavasani S, Bockermann R, Mondoc E, Holmdahl R, Issazadeh-Navikas S. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J Immunol 2004; 172(1)186–194
   PubMed Web of Science ®Google Scholar
• Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000; 290(5497)1768–1771
   PubMed Web of Science ®Google Scholar
• Abromson-Leeman S, Maverakis E, Bronson R, Dorf ME. CD40-mediated activation of T cells accelerates, but is not required for, encephalitogenic potential of myelin basic protein-recognizing T cells in a model of progressive experimental autoimmune encephalomyelitis. Eur J Immunol 2001; 31(2)527–538
   PubMed Web of Science ®Google Scholar
• Ford ML, Onami TM, Sperling AI, Ahmed R, Evavold BD. CD43 modulates severity and onset of experimental autoimmune encephalomyelitis. J Immunol 2003; 171(12)6527–6533
   PubMed Web of Science ®Google Scholar
• Grewal IS, Foellmer HG, Grewal KD, Wang H, Lee WP, Tumas D, Janeway CA, Jr., Flavell RA. CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis. Immunity 2001; 14(3)291–302
   PubMed Web of Science ®Google Scholar
• Tompkins SM, Padilla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol 2002; 168(8)4173–4183
   PubMed Web of Science ®Google Scholar
• Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8(6)620–624
   PubMed Web of Science ®Google Scholar
• Hilliard BA, Mason N, Xu L, Sun J, Lamhamedi-Cherradi SE, Liou HC, Hunter C, Chen YH. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002; 110(6)843–850
   PubMed Web of Science ®Google Scholar
• Liu L, Huang D, Matsui M, He TT, Hu T, Demartino J, Lu B, Gerard C, Ransohoff RM. Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3 − / − mice with experimental autoimmune encephalomyelitis. J Immunol 2006; 176(7)4399–4409
   PubMed Web of Science ®Google Scholar
• Bakker AB, Hoek RM, Cerwenka A, Blom B, Lucian L, McNeil T, Murray R, Phillips LH, Sedgwick JD, Lanier LL. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 2000; 13(3)345–353
   PubMed Web of Science ®Google Scholar
• Agrawal A, Dillon S, Denning TL, Pulendran B. ERK1 − / − mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J Immunol 2006; 176(10)5788–5796
   PubMed Web of Science ®Google Scholar
• Abdul-Majid KB, Stefferl A, Bourquin C, Lassmann H, Linington C, Olsson T, Kleinau S, Harris RA. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand J Immunol 2002; 55(1)70–81
   PubMed Web of Science ®Google Scholar
• Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den Oord J, Sciot R, Meinhardt T, Hammerling G, Opdenakker G, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999; 104(11)1507–1515
   PubMed Web of Science ®Google Scholar
• Ikushima H, Kanaoka M, Kojima S. Cutting edge: Requirement for growth hormone-releasing hormone in the development of experimental autoimmune encephalomyelitis. J Immunol 2003; 171(6)2769–2772
   PubMed Web of Science ®Google Scholar
• Teuscher C, Poynter ME, Offner H, Zamora A, Watanabe T, Fillmore PD, Zachary JF, Blankenhorn EP. Attenuation of Th1 effector cell responses and susceptibility to experimental allergic encephalomyelitis in histamine H2 receptor knockout mice is due to dysregulation of cytokine production by antigen-presenting cells. Am J Pathol 2004; 164(3)883–892
   PubMed Web of Science ®Google Scholar
• Samoilova EB, Horton JL, Chen Y. Experimental autoimmune encephalomyelitis in intercellular adhesion molecule-1-deficient mice. Cell Immunol 1998; 190(1)83–89
   PubMed Web of Science ®Google Scholar
• Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001; 409(6816)97–101
   PubMed Web of Science ®Google Scholar
• Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996; 26(7)1641–1646
   PubMed Web of Science ®Google Scholar
• Tran EH, Prince EN, Owens T. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 2000; 164(5)2759–2768
   PubMed Web of Science ®Google Scholar
• Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T, Holmdahl R, Issazadeh-Navikas S. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 2003; 170(9)4776–4784
   PubMed Web of Science ®Google Scholar
• Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 1998; 161(7)3299–3306
   PubMed Web of Science ®Google Scholar
• Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110(4)493–497
   PubMed Web of Science ®Google Scholar
• Zhang GX, Yu S, Gran B, Li J, Siglienti I, Chen X, Calida D, Ventura E, Kamoun M, Rostami A. Role of IL-12 receptor beta 1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis. J Immunol 2003; 171(9)4485–4492
   PubMed Web of Science ®Google Scholar
• Zhang GX, Gran B, Yu S, Li J, Siglienti I, Chen X, Kamoun M, Rostami A. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 2003; 170(4)2153–2160
   PubMed Web of Science ®Google Scholar
• Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 2000; 165(6)3099–3104
   PubMed Web of Science ®Google Scholar
• Petitto JM, Streit WJ, Huang Z, Butfiloski E, Schiffenbauer J. Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 2000; 285(1)66–70
   PubMed Web of Science ®Google Scholar
• Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: A study in gene-targeted mice. Eur J Immunol 1998; 28(5)1727–1737
   PubMed Web of Science ®Google Scholar
• Sahrbacher UC, Lechner F, Eugster HP, Frei K, Lassmann H, Fontana A. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur J Immunol 1998; 28(4)1332–1338
   PubMed Web of Science ®Google Scholar
• Buch T, Uthoff-Hachenberg C, Waisman A. Protection from autoimmune brain inflammation in mice lacking IFN-regulatory factor-1 is associated with Th2-type cytokines. Int Immunol 2003; 15(7)855–859
   PubMed Web of Science ®Google Scholar
• Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 1997; 186(8)1233–1240
   PubMed Web of Science ®Google Scholar
• Du C, Sriram S. Increased severity of experimental allergic encephalomyelitis in lyn − / − mice in the absence of elevated proinflammatory cytokine response in the central nervous system. J Immunol 2002; 168(6)3105–3112
   PubMed Web of Science ®Google Scholar
• Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001; 193(6)713–726
   PubMed Web of Science ®Google Scholar
• Delarasse C, Daubas P, Mars LT, Vizler C, Litzenburger T, Iglesias A, Bauer J, Della Gaspera B, Schubart A, Decker L, et al. Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest 2003; 112(4)544–553
   PubMed Web of Science ®Google Scholar
• Brennan M, Gaur A, Pahuja A, Lusis AJ, Reynolds WF. Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 112(1–2)97–105
   PubMed Web of Science ®Google Scholar
• Lyons JA, Ramsbottom MJ, Cross AH. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol 2002; 32(7)1905–1913
   PubMed Web of Science ®Google Scholar
• Hilliard B, Samoilova EB, Liu TS, Rostami A, Chen Y. Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice: Roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J Immunol 1999; 163(5)2937–2943
   PubMed Web of Science ®Google Scholar
• Carboni S, Aboul-Enein F, Waltzinger C, Killeen N, Lassmann H, Pena-Rossi C. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 2003; 145(1–2)1–11
   PubMed Web of Science ®Google Scholar
• Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol 2001; 167(5)2991–2999
   PubMed Web of Science ®Google Scholar
• Copray S, Kust B, Emmer B, Lin MY, Liem R, Amor S, de Vries H, Floris S, Boddeke E. Deficient p75 low-affinity neurotrophin receptor expression exacerbates experimental allergic encephalomyelitis in C57/BL6 mice. J Neuroimmunol 2004; 148(1–2)41–53
   PubMed Web of Science ®Google Scholar
• Raijmakers R, Vogelzangs J, Raats J, Panzenbeck M, Corby M, Jiang H, Thibodeau M, Haynes N, Van Venrooij WJ, Pruijn GJ, et al. Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J Comp Neurol 2006; 498(2)217–226
   PubMed Web of Science ®Google Scholar
• Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S, Ruddle NH, Engelhardt B, Madri JA. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 2002; 109(3)383–392
   PubMed Web of Science ®Google Scholar
• Malipiero U, Frei K, Spanaus KS, Agresti C, Lassmann H, Hahne M, Tschopp J, Eugster HP, Fontana A. Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. Eur J Immunol 1997; 27(12)3151–3160
   PubMed Web of Science ®Google Scholar
• Tan SL, Zhao J, Bi C, Chen XC, Hepburn DL, Wang J, Sedgwick JD, Chintalacharuvu SR, Na S. Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C theta-deficient mice. J Immunol 2006; 176(5)2872–2879
   PubMed Web of Science ®Google Scholar
• Natarajan C, Muthian G, Barak Y, Evans RM, Bright JJ. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol 2003; 171(11)5743–5750
   PubMed Web of Science ®Google Scholar
• Harroch S, Furtado GC, Brueck W, Rosenbluth J, Lafaille J, Chao M, Buxbaum JD, Schlessinger J. A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nat Genet 2002; 32(3)411–414
   PubMed Web of Science ®Google Scholar
• Chen L, Brosnan CF. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R − / − mice: Evidence for loss of apoptotic activity in lymphocytes. J Immunol 2006; 176(5)3115–3126
   PubMed Web of Science ®Google Scholar
• Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, Khoury SJ. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001; 108(5)739–747
   PubMed Web of Science ®Google Scholar
• Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, Piesche M, Schroers R, Weiss E, Kirschning CJ, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006; 116(2)456–464
   PubMed Web of Science ®Google Scholar
• Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997; 186(9)1585–1590
   PubMed Web of Science ®Google Scholar
• Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4(1)78–83
   PubMed Web of Science ®Google Scholar
• Bachmann R, Eugster HP, Frei K, Fontana A, Lassmann H. Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol 1999; 154(5)1417–1422
   PubMed Web of Science ®Google Scholar
• Suvannavejh GC, Lee HO, Padilla J, Dal Canto MC, Barrett TA, Miller SD. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 2000; 205(1)24–33
   PubMed Web of Science ®Google Scholar
• Lu W, Bhasin M, Tsirka SE. Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J Neurosci 2002; 22(24)10781–10789
   PubMed Web of Science ®Google Scholar
• Korn T, Fischer KD, Girkontaite I, Kollner G, Toyka K, Jung S. Vav1-deficient mice are resistant to MOG-induced experimental autoimmune encephalomyelitis due to impaired antigen priming. J Neuroimmunol 2003; 139(1–2)17–26
   PubMed Web of Science ®Google Scholar